Qbrexza (Glycopyrronium) Wipes: Prescription Treatment Review

What Is Qbrexza?

Qbrexza (glycopyrronium tosylate) is a prescription medicated cloth wipe approved by the FDA in June 2018 for the treatment of primary axillary (underarm) hyperhidrosis in adults and children age 9 and older. It was the first topical anticholinergic specifically developed and approved for excessive sweating — a significant milestone in hyperhidrosis treatment.

If you've been frustrated by clinical antiperspirants that don't work well enough or cause too much skin irritation, Qbrexza offers a fundamentally different approach. Instead of physically blocking sweat ducts with aluminum plugs, Qbrexza works at the nerve level — it blocks the chemical signal that tells your sweat glands to produce sweat. This makes it a genuine alternative, not just another version of the same thing.

Developed by Dermira (now part of UCB), Qbrexza is available as individually packaged pre-moistened cloth wipes. You use one wipe per day, applied to both underarms, and the medication provides 24 hours of sweat reduction.

How Qbrexza Works

The Mechanism

Qbrexza contains glycopyrronium tosylate, a topical anticholinergic agent. Here's how it reduces sweating:

1. Application: You wipe the medicated cloth across your underarm skin, depositing glycopyrronium tosylate on the surface.

2. Absorption: The medication penetrates the outer layers of skin and reaches the nerve endings near the eccrine sweat glands.

3. Receptor blockade: Glycopyrronium competitively binds to muscarinic (M3) acetylcholine receptors on the sweat glands. These are the same receptors that normally receive the "produce sweat" signal from sympathetic nerves.

4. Signal interruption: With the receptors blocked, acetylcholine (the neurotransmitter that triggers sweating) cannot activate the sweat glands. No signal, no sweat.

5. Duration: The effect lasts approximately 24 hours, which is why once-daily application is sufficient.

How It Differs from Antiperspirants

| Feature | Qbrexza | Aluminum Chloride Antiperspirants | |---------|---------|----------------------------------| | Mechanism | Blocks nerve signals to sweat glands | Physically plugs sweat ducts | | Onset | Within 1-2 hours | 6-8 hours (overnight) | | Application time | Morning | Night (must apply to dry skin) | | Skin irritation | Mild (different type) | Moderate to significant | | Works on wet skin | Yes | No (must be completely dry) | | Effectiveness | ~50% sweat reduction | 40-60% reduction |

How It Differs from Oral Anticholinergics

Qbrexza provides localized anticholinergic effect — the medication is delivered directly to the sweat glands in the underarm area, with relatively limited systemic absorption. Oral medications like glycopyrrolate and oxybutynin affect the entire body, which provides broader sweat reduction but also more systemic side effects.

Interestingly, glycopyrronium (in Qbrexza) and glycopyrrolate (the oral medication) are closely related compounds — glycopyrronium tosylate is the topical formulation of the same anticholinergic agent. The topical delivery limits how much enters your bloodstream, reducing (but not eliminating) systemic side effects.

Clinical Trial Results

The ATMOS-1 and ATMOS-2 Trials

Qbrexza's FDA approval was based on two large, randomized, double-blind, vehicle-controlled Phase 3 trials:

ATMOS-1 (n=344):

• Primary endpoint: Patients achieving a 4-point improvement in gravimetrically measured sweat production at Week 4
• Qbrexza group: 66.1% met the endpoint vs. 26.9% in the placebo group
• Mean sweat reduction: 50% from baseline

ATMOS-2 (n=353):

• Same primary endpoint
• Qbrexza group: 53.4% vs. 28.3% in placebo
• Mean sweat reduction: 47% from baseline

HDSS Score Improvements

The Hyperhidrosis Disease Severity Scale also showed significant improvement:

• 59.2% of Qbrexza patients achieved an HDSS score of 1 or 2 (tolerable sweating) by Week 4, compared to 35.6% of placebo patients
• Many patients reported improvement within the first week
• Results maintained throughout the 4-week study period

Patient-Reported Outcomes

In open-label extension studies lasting up to 44 weeks:

• Sustained effectiveness with continued daily use
• Patient satisfaction remained high
• No evidence of tachyphylaxis (reduced effectiveness over time)

How to Use Qbrexza

Application Instructions

1. Open the individual foil pouch and remove the pre-moistened cloth wipe.
2. Unfold the cloth completely.
3. Wipe the cloth across one underarm in a single, even stroke.
4. Flip the cloth and repeat on the other underarm using the other side.
5. Discard the cloth — each wipe is single-use.
6. Wash your hands immediately with soap and water after application. This is important to avoid accidentally transferring the medication to your eyes or other sensitive areas.
7. Avoid touching your face or eyes until you've washed your hands thoroughly.

Best Practices

• Apply in the morning — unlike aluminum chloride antiperspirants that must be applied at night, Qbrexza works best when applied in the morning as part of your regular routine.
• Apply to clean, intact skin — shower first, but the skin doesn't need to be bone-dry like it does for antiperspirants.
• Don't apply to broken or irritated skin — open cuts, rashes, or recently shaved skin (wait 24 hours after shaving).
• One wipe per day, both underarms — don't use extra wipes for additional effect.
• Can be combined with deodorant — Qbrexza reduces sweating; deodorant addresses odor. Apply deodorant after Qbrexza has dried.

What to Expect

• Day 1-3: Some patients notice initial improvement within the first few applications.
• Week 1-2: Progressive improvement in sweat reduction.
• Week 3-4: Full effectiveness typically reached — approximately 50% reduction in underarm sweating.
• Ongoing: Continue daily use to maintain results. Sweating returns within 1-3 days of stopping.

Side Effects

Common Side Effects

Dry mouth (16.9% of patients): The most frequently reported side effect. Despite topical application, some glycopyrronium is absorbed systemically and can affect salivary glands. For most patients, it's mild — noticeable but not distressing. Stay hydrated and use sugar-free gum or lozenges.

Mydriasis — dilated pupils (6.8%): Occurs when the medication inadvertently contacts the eyes (usually via unwashed hands). This is why hand-washing after application is essential. Symptoms include blurred near vision and sensitivity to bright light. It's temporary and resolves within hours.

Oropharyngeal pain — sore throat (3.4%): Related to the drying effect on mucous membranes. Usually mild.

Application site pain (2.3%): Mild burning or stinging at the application site. Typically transient and much less severe than irritation from aluminum chloride antiperspirants.

Less Common Side Effects

• Urinary hesitancy (difficulty starting urination)
• Blurred vision (from systemic anticholinergic effect, not eye contact)
• Nasal dryness
• Constipation
• Headache

Serious Concerns

Heat-related illness: Like all anticholinergic treatments, Qbrexza can impair the body's ability to cool through sweating. While the risk is lower with topical application than oral medications, exercise caution during intense physical activity in hot environments.

Urinary retention: Rarely, anticholinergics can cause inability to urinate. Seek medical attention if this occurs.

Eye exposure: If Qbrexza contacts the eyes, it can cause temporary blurred vision and pupil dilation. Flush eyes with water and avoid driving until vision clears.

Who Should Not Use Qbrexza

• Patients with glaucoma or at risk for angle-closure glaucoma
• Patients with conditions that could be worsened by anticholinergic effects (urinary retention, gastrointestinal obstruction)
• Patients with known hypersensitivity to glycopyrronium or any component

Cost and Insurance

Retail Pricing

Qbrexza's retail price without insurance is significant:

• 30-day supply (30 individual wipes): $550-$700
• Annual cost without insurance: $6,600-$8,400

This is one of the most expensive routine treatments for hyperhidrosis, which is a major barrier for many patients.

With Insurance

Insurance coverage for Qbrexza varies but has improved since its launch:

• With commercial insurance: Copays typically range from $25-$75/month, depending on your plan and formulary tier
• With manufacturer copay assistance: UCB offers a copay card for commercially insured patients that can reduce out-of-pocket costs to as low as $0-$35/month
• Medicare Part D: Coverage varies; many plans include it on a specialty tier with higher copays ($50-$200/month)
• Medicaid: Coverage varies by state

Getting Coverage

If your insurance doesn't cover Qbrexza or requires prior authorization:

1. Document failed first-line treatment: Your dermatologist should note that you've tried and failed clinical antiperspirants.
2. HDSS documentation: Include your Hyperhidrosis Disease Severity Scale score (3 or 4 for "severe").
3. Prior authorization: Your doctor's office can submit prior authorization, which many insurers require.
4. Appeal if denied: Include supporting documentation from the ATMOS trials and treatment guidelines.

Cost Comparison

| Treatment | Monthly Cost | Annual Cost | |-----------|-------------|-------------| | Qbrexza (without insurance) | $550-$700 | $6,600-$8,400 | | Qbrexza (with insurance + copay card) | $0-$75 | $0-$900 | | OTC clinical antiperspirant | $4-$10 | $50-$120 | | Prescription Drysol | $15-$40 | $90-$480 | | Oral glycopyrrolate (generic) | $15-$50 | $180-$600 | | Botox (divided monthly) | $125-$250 | $1,500-$3,000 |

If you can access Qbrexza through insurance with a copay card, it's extremely cost-effective. Without insurance, it's one of the most expensive options and hard to justify for many patients.

Qbrexza vs. Other Treatments

Qbrexza vs. Clinical Antiperspirants

Choose Qbrexza if:

• Aluminum chloride antiperspirants cause too much skin irritation
• You dislike the nighttime application requirement
• You want a different mechanism of action
• Your insurance covers it affordably

Choose antiperspirants if:

• Cost is a primary concern
• You want an OTC option (no prescription needed)
• You tolerate aluminum chloride well
• You prefer the lowest possible intervention first

Qbrexza vs. Oral Glycopyrrolate

Choose Qbrexza if:

• Your hyperhidrosis is primarily axillary (underarms)
• You want to minimize systemic side effects
• You're concerned about long-term anticholinergic cognitive effects

Choose oral medications if:

• You sweat excessively in multiple body areas
• You need whole-body sweat reduction
• Cost without insurance is a factor (oral glycopyrrolate is much cheaper)

Qbrexza vs. Botox

Choose Qbrexza if:

• You prefer a non-injectable daily treatment
• You want to try a less invasive option first
• Cost with insurance is favorable
• You dislike needles

Choose Botox if:

• You want more potent sweat reduction (82-87% vs. ~50%)
• You prefer infrequent treatments (every 6-12 months)
• Your insurance covers Botox
• Qbrexza hasn't provided adequate relief

Qbrexza vs. miraDry

Choose Qbrexza if:

• You want a reversible, non-procedural option
• You're not ready for a permanent procedure
• Cost is a concern (miraDry is $2,000-$3,000 upfront)

Choose miraDry if:

• You want permanent results
• You want to stop daily treatment routines
• You can afford the upfront cost
• You've already tried Qbrexza or similar treatments

Off-Label Uses

While Qbrexza is FDA-approved only for axillary hyperhidrosis, some dermatologists prescribe it off-label for:

• Craniofacial hyperhidrosis (forehead, scalp) — the wipes can be applied to the face, though extra caution is needed regarding eye exposure
• Other body areas — some patients use the wipes on the chest, back, or other sweating zones
• Compensatory sweating — after ETS surgery, for sweating in new areas

Off-label effectiveness data is limited, but the mechanism (blocking sweat gland activation) should theoretically work wherever the medication can reach the sweat glands topically.

Tips for Getting the Most from Qbrexza

1. Be consistent. Daily use provides the best results. Missing days allows sweating to return.
2. Wash your hands every time. The most common preventable side effect (dilated pupils) comes from touching your eyes after application.
3. Give it time. While some patients notice improvement within days, full effectiveness may take 2-4 weeks.
4. Combine with deodorant. Qbrexza reduces sweat; add deodorant for odor control.
5. Store properly. Keep at room temperature, away from heat and moisture.
6. Use the copay card. If you have commercial insurance, UCB's copay assistance can dramatically reduce your cost.
7. Track your results. Use the HDSS scale or simply note your daily sweat level to objectively assess improvement.

Frequently Asked Questions

How effective is Qbrexza for underarm sweating?

Clinical trials showed an average 47-50% reduction in underarm sweat production, with 53-66% of patients achieving the primary efficacy endpoint. While not as dramatic as Botox (82-87%), Qbrexza provides meaningful improvement for most users. Patient-reported outcomes show high satisfaction rates.

How quickly does Qbrexza start working?

Some patients notice reduced sweating within the first few days. The full effect typically develops over 2-4 weeks of consistent daily use. Unlike antiperspirants (which require nighttime application to dry skin), Qbrexza can be applied in the morning and begins working within 1-2 hours.

Can I use Qbrexza on my hands?

Qbrexza is FDA-approved only for underarm use. Some dermatologists prescribe it off-label for other areas, but there are practical challenges with palmar use — you'd need to keep your hands still while the medication absorbs, and the wipes are designed for underarm surface area. For hand sweating, iontophoresis is generally more effective.

What happens if I stop using Qbrexza?

Sweating returns to its previous level within 1-3 days of stopping Qbrexza. The medication does not permanently alter your sweat glands — it temporarily blocks the nerve signals each time you apply it. There is no rebound effect (sweating doesn't become worse than before).

Is Qbrexza safe for teenagers?

Qbrexza is FDA-approved for patients aged 9 and older. The ATMOS clinical trials included adolescent participants (ages 9-17), and the safety and efficacy data supported approval for this age group. Common side effects in adolescents were similar to adults.

Can I use Qbrexza with other hyperhidrosis treatments?

Yes. Qbrexza can be combined with other treatments:

• Qbrexza for underarms + iontophoresis for hands/feet
• Qbrexza + deodorant for odor control
• Qbrexza + low-dose oral glycopyrrolate for multi-area coverage
• Consult your dermatologist before combining with other anticholinergics to avoid additive side effects

Does Qbrexza cause dry mouth?

Dry mouth is the most commonly reported side effect, affecting approximately 17% of patients. It's generally mild — less severe than with oral anticholinergics because topical delivery limits systemic absorption. Stay hydrated and use sugar-free gum if it bothers you.

Why is Qbrexza so expensive?

As a branded prescription product with no generic equivalent (as of 2026), Qbrexza carries the high price typical of specialty pharmaceuticals. The retail price of $550-$700/month reflects both development costs and the relatively small patient population. The manufacturer offers copay assistance programs that can significantly reduce out-of-pocket costs for commercially insured patients.

Sources

1. Glaser DA, et al. "Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials." Journal of the American Academy of Dermatology. 2019;80(1):128-138.
2. Hebert AA, et al. "Safety and efficacy of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: long-term follow-up." Dermatologic Surgery. 2019;45(Suppl 1):S44-S51.
3. Dermira Inc. "QBREXZA (glycopyrronium) cloth, 2.4%, for topical use. Prescribing Information." US Food and Drug Administration.
4. Pariser DM, et al. "Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials." American Journal of Clinical Dermatology. 2019;20(1):135-145.
5. International Hyperhidrosis Society. "Qbrexza." www.sweathelp.org. Accessed March 2026.
6. UCB. "Qbrexza patient support program." www.qbrexza.com. Accessed March 2026.